Publications by authors named "K Halligan"
Article Synopsis
- Metabolic changes in pediatric diffuse midline glioma are influenced by the H3K27M histone mutation, which activates oncogenic pathways.
- The RAS pathway and ERK5 kinase are crucial for tumor growth in these gliomas, with ERK5 playing a key role in cell proliferation and glycolysis.
- Targeting the ERK5-PFKFB3 signaling axis with multi-targeted drugs could be an effective treatment strategy for patients with this type of cancer.
Progressive familial intrahepatic cholestasis type 1 (PFIC1) is an inherited, progressive cholestatic liver disease. Here, we present an approach to the treatment of Ewing sarcoma in a patient with PFIC1. The diagnosis of PFIC1 presents a unique challenge in the treatment of Ewing sarcoma, as the standard-of-care vincristine, doxorubicin, cyclophosphamide/ifosfamide and etoposide chemotherapy backbone for Ewing sarcoma therapy treatment relies heavily on intact hepatic metabolism.
View Article and Find Full Text PDFDiffuse midline gliomas (DMGs) bearing driver mutations of histone 3 lysine 27 (H3K27M) are incurable brain tumors with unique epigenomes. Here, we generated a syngeneic H3K27M mouse model to study the amino acid metabolic dependencies of these tumors. H3K27M mutant cells were highly dependent on methionine.
View Article and Find Full Text PDFBackground: Tranexamic acid reduces blood loss in surgery and the risk of death in trauma patients. Meta-analyses of small trials suggest that tranexamic acid decreases the number of deaths from gastrointestinal bleeding, but these meta-analyses are prone to selection bias.
Objective: The trial provides reliable evidence of the effect of tranexamic acid on mortality, rebleeding and complications in significant acute gastrointestinal bleeding.